The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study
{{output}}
Background: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder caused by severe ADAMTS13 deficiency, leading to microvascular platelet-rich thrombi, hemolysis, and organ damage, mainly... ...